瑞舒伐他汀强化调脂对急性心肌梗死介入术后氧化应激和炎症的影响  

Effect of rosuvastatin intensive lipid-lowering on oxidative stress and inflammation reaction in AMI patients undergoing PCI

作　　者：高好考[1] 陈青 栾荣华[1] 王琼[1] 

机构地区：[1]第四军医大学西京医院心脏内科,陕西西安710021 [2]延安大学咸阳医院/中铁二十局中心医院心脏病科,陕西咸阳712000

出　　处：《临床医学研究与实践》2018年第3期8-9,共2页Clinical Research and Practice

基　　金：国家自然基金(No.81570210)

摘　　要：目的探讨不同剂量瑞舒伐他汀强化调脂对急性心肌梗死(AMI)患者急诊经皮冠状动脉介入治疗(PCI)的影响。方法选取我院收治的100例需行PCI术的AMI患者,术前随机分为两组,各50例,均予以基础治疗。两组均加用瑞舒伐他汀片治疗,对照组剂量为10 mg,观察组剂量为20 mg。比较两组患者治疗前、后SOD、MDA、hs-CRP水平及不良反应总发生率。结果治疗4周后,观察组患者的血清SOD和MDA、hs-CRP水平均明显优于对照组和治疗前(P<0.05)。两组患者的不良反应总发生率比较,差异不显著(P>0.05)。结论瑞舒伐他汀强化调脂治疗可以减少SOD的消耗量,缓解患者体内炎症反应和血清hs-CRP水平。Objective To investigate the effects of different doses of rosuvastatin intensive lipid-lowering on oxidative stress and inflammation reaction in acute myocardial infarction（AMI） patients undergoing percutaneous coronary interven-tion（PCI）. Methods A total of 100 patients with AMI undergoing PCI admitted in our hospital were selected and randomly divided into two groups before surgery, with 50 cases in each group, both groups were given basic treatment. Both group were treated with rosuvastatin tablets treatment, the dose in the control group was 10 mg, the observation group was 20 mg.The levels of SOD, MDA, hs-CRP before and after treatment and the total incidence of adverse reactions in both groups were compared. Results After 4 weeks of treatment, the levels of SOD and MDA and hs-CRP in the observation group were significantly better than those in the control group and before treatment（P〈0.05）. There was no significant difference in the total incidences of adverse reactions between the two groups（P〉0.05）. Conclusion Rosuvastatin intensive lipid-lowering treatment can reduce the consumption of SOD, relieve the patients＇ inflammatory response and the level of serum hs-CRP.

关 键 词：急性心肌梗死 经皮冠状动脉介入治疗 瑞舒伐他汀 

分 类 号：R542.22[医药卫生—心血管疾病]